Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 22, 2024 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration...
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
October 31, 2023 07:30 ET
|
Harmony Biosciences
Continued Strong Growth with WAKIX® (pitolisant) Net Revenue of $160.3 Million for Third Quarter 2023; Increased ~37% Year-over-Year Average Number of Patients on WAKIX Increased by ~350...
Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates
August 01, 2023 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue Increased ~25% Year-over-Year to $134.2 Million for Second Quarter 2023 Average Number of Patients on WAKIX Increased by ~350 Sequentially to ~5,450 for Second Quarter...
Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
May 02, 2023 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue Increased ~40% Year-over-Year to $119.1 Million for First Quarter 2023 Average Number of Patients on WAKIX Increased ~1,200 Year-over-Year to ~5,100 for First Quarter...
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 21, 2023 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue Increased ~41% Year-over-Year to $128.3 Million for Fourth Quarter 2022; ~43% to $437.9 Million for Full Year 2022 Achieved Net Income of $181.5 Million for Full Year...
Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates
November 01, 2022 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue of $117.2 Million for Third Quarter 2022 Increase of ~45% vs. the Same Period in 2021 Average Number of Patients on WAKIX Increased to ~4,600 Prader-Willi Syndrome...
Harmony Biosciences Reports Second Quarter 2022 Financial Results and Business Updates
August 02, 2022 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue of $107.0 Million for Second Quarter 2022 Increase of 45% vs. the Same Period in 2021 Average Number of Patients on WAKIX Increased to ~4,300 Signs New Agreement with...
Harmony Biosciences Reports First Quarter 2022 Financial Results and Business Updates
May 03, 2022 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue of $85.3 Million for First Quarter 2022 Increase of 43% vs. the Same Period in 2021 WAKIX Surpasses $500 Million in Cumulative Net Revenue Since Launch Initiated...
Harmony Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
February 28, 2022 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue Increased 62% Year-over-Year to $91.2 Million for Fourth Quarter 2021 and 91% to $305.4 Million for Full Year Achieved First Full Year of Profitability and Net income...
Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business Updates
November 09, 2021 07:30 ET
|
Harmony Biosciences
WAKIX® (pitolisant) Net Revenue of $80.7 Million for Third Quarter 2021 Increase of 77% vs. the Same Period in 2020 Average Number of Patients on WAKIX Increased to ~3,500 Announced Inclusion of...